The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.
Eric T. Wittbrodt, PharmD, MPH
Advertisement
Articles by Eric T. Wittbrodt, PharmD, MPH
Advertisement
Latest Updated Articles
- Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population
Published: April 14th 2018 | Updated:
- Comparison of Low-Dose Liraglutide Use Versus Other GLP-1 Receptor Agonists in Patients Without Type 2 Diabetes
Published: April 14th 2018 | Updated:
- Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”
Published: April 8th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
4
Improving Access and Care for All Patients With Atopic Dermatitis
5
